Loading...
•
Sep 30, 2023
Fulcrum Therapeutics Q3 2023 Earnings Report
Announced financial results for the third quarter of 2023 and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported their Q3 2023 financial results, completed enrollment in the Phase 3 REACH trial of losmapimod in FSHD, and had the clinical hold for pociredir in SCD lifted.
Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024.
The U.S. Food and Drug Administration (FDA) lifted clinical hold for pociredir in sickle cell disease (SCD); trial reinitiation underway.
Cash runway extended into 2026.
Collaboration revenue was $0.8 million for the third quarter of 2023.
Forward Guidance
Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...